Lonza walkersville, INC.1110291 TN17018683 niddk mchb will use human CD34+ cells as our model studies to conduct basic and clinical research on selected inherited and acquired diseases of human blood,…

Ended Awarded

Contract number
HHSN26800001
Awardee
Awarding agency
Obligated
$12,385

Award facts

Contract value 100% obligated
$12,384.50 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
325413 In-Vitro Diagnostic Substance Manufacturing
PSC
6505 Drugs And Biologicals
Set-aside
No set-aside
Competition
Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Walkersville, MD 21793, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Description

As the agency reported it.

Lonza walkersville, INC.1110291 TN17018683 niddk mchb will use human CD34+ cells as our model studies to conduct basic and clinical research on selected inherited and acquired diseases of human blood, utilizing contemporary biochemical, molecular and physiological techniques. Quote no.20086837

Quick answers

Who was awarded contract HHSN26800001?

HHSN26800001 was awarded to Lonza Walkersville, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on June 27, 2017.

How much is contract HHSN26800001 worth?

The government has obligated $12,385 on HHSN26800001.

Is contract HHSN26800001 an order under another contract?

Yes. HHSN26800001 is a BPA call under HHSN263201600052B, a blanket purchase agreement.

Was contract HHSN26800001 competed?

The extent of competition for HHSN26800001 was competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login